Haikala et al. reported that EGFR inhibition by osimertinib leads to increased HER3 membrane expression and promotes HER3-DXd ADC internalization and efficacy, supporting the clinical development of an EGFR inhibitor/HER3-DXd combination in EGFR-mutant lung cancer preclinically [106]. Here, ERBB3 is linked to lung carcinoma.